2023-10-19T01:06:13+03:00[Europe/Moscow] en true <p>alkylating agents, antimetabolites, antimicrotubule, topoisomerase</p>, <p>b</p>, <p>doubling time </p>, <p>d</p>, <p>c</p>, <p>specific for a single agent, MD resistance, mutation of target enzymes</p>, <p>a</p>, <p>undruggable genomic drivers, tumor growth kinetics, selective therapeutic pressure, tumor heterogeneity </p>, <p>toxicity that does not overlap </p>, <p>effectiveness in monotherapy </p>, <p>efficacy, toxicity, mechanism of interaction, optimum scheduling, avoidance of dose changes</p>, <p>anti-EGFR, KRAS, anti-angiogenic </p>, <p>checkpoint inhibitors </p>, <p>b</p>, <p>a</p>, <p>b</p>, <p>alkylating agents, platinum analogs </p>, <p>b,d</p>, <p>a,c</p>, <p>d</p>, <p>erlotinib, afatinib, osimertinib, gefitinib </p>, <p>Sotorasib </p>, <p>bevacizumab </p>, <p>cisplatin, carboplatin</p>, <p>pemetrexed, gemcitabine</p>, <p>paclitaxel, docetaxel </p>, <p>topotecan, irinotecan, etoposide </p> flashcards
Pharmacology of Lung-Cancer (Overview)

Pharmacology of Lung-Cancer (Overview)

Customize
collection saved
Share
Long Term Learning Spaced Repetition
Add to Long Term Learning Desk
Fast learning Repeat this set of flashcards
Preview Test Spell
Play
Match
Review

  • alkylating agents, antimetabolites, antimicrotubule, topoisomerase

    What are our chemotherapy agents? (4)

  • b

    Involves no response from first drug exposure.

    a) tumor heterogeneity

    b) Undruggable genomic drivers

    c) selective therapeutic pressure

    d) tumor growth kinetics

  • doubling time

    As the tumor Increases in size; ________ increases.

  • d

    This form of drug resistance results in a smaller fraction of cells getting killed.

    a) tumor heterogeneity

    b) undruggable genomic drivers

    c) selective therapeutic pressure

    d) tumor growth kinetics

  • c

    This type of drug resistance results in survival of the fittest.

    a) tumor heterogeneity

    b) undruggable genomic drivers

    c) selective therapeutic pressure

    d) tumor growth kinetics

  • specific for a single agent, MD resistance, mutation of target enzymes

    What are the characteristics of acquired resistance in cancer cells? (3)

  • a

    This form of drug resistance results in different genetic components in the tumor.

    a) tumor heterogeneity

    b) undruggable genomic drivers

    c) selective therapeutic pressure

    d) tumor growth kinetics

  • undruggable genomic drivers, tumor growth kinetics, selective therapeutic pressure, tumor heterogeneity

    What are the forms of Cancer-Drug resistance? (4)

  • toxicity that does not overlap

    When selecting chemotherapy agents, choose one with ___________ with the other drugs in the combination.

  • effectiveness in monotherapy

    All drugs selected for combination therapy must exhibit what?

  • efficacy, toxicity, mechanism of interaction, optimum scheduling, avoidance of dose changes

    What are the guidelines regarding Chemo-Combination therapy? (5)

  • anti-EGFR, KRAS, anti-angiogenic

    What are our targeted therapeutics? (3)

  • checkpoint inhibitors

    What is our immunotherapy option?

  • b

    Which is cytostatic?

    a) Chemotherapy

    b) Targeted Therapy

  • a

    Which acts on rapidly dividing cells?

    a) Chemotherapy

    b) Targeted Therapy

  • b

    Which acts on targets associated with the proliferation of cancer cells?

    a) Chemotherapy

    b) Targeted Therapy

  • alkylating agents, platinum analogs

    What are the Cell Cycle-Nonspecific Agents? (2)

  • b,d

    Which act on the S-Phase?

    a) Vinca alkaloids

    b) Antimetabolites

    c) Taxanes

    d) Topoisomerase inhibitors

  • a,c

    Which act on the M phase?

    a) Vinca alkaloids

    b) Antimetabolites

    c) Taxanes

    d) Topoisomerase inhibitors

  • d

    Which act on the G2 phase?

    a) Vinca alkaloids

    b) Antimetabolites

    c) Taxanes

    d) Topoisomerase inhibitors

  • erlotinib, afatinib, osimertinib, gefitinib

    What are the EGFR inhibitors? (4)

  • Sotorasib

    What is the KRAS inhibitor?

  • bevacizumab

    What is the VEGF therapy?

  • cisplatin, carboplatin

    What are the alkylating agents? (2)

  • pemetrexed, gemcitabine

    What are the antimetabolites? (2)

  • paclitaxel, docetaxel

    What are the Taxanes? * Antimicrotubule (2)

  • topotecan, irinotecan, etoposide

    What are the Topoisomerase inhibitors? (3)